<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943602</url>
  </required_header>
  <id_info>
    <org_study_id>CaboPen</org_study_id>
    <nct_id>NCT03943602</nct_id>
  </id_info>
  <brief_title>Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)</brief_title>
  <acronym>CaboPen</acronym>
  <official_title>Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label,
      single-center, phase 2, single-arm trial (CaboPen)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      an open-label, single-center, phase 2, single-arm trial
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response -rate by RECIST v1.1 criteria</measure>
    <time_frame>40 months</time_frame>
    <description>Assessment of response-rate by RECIST v1.1. Complete response + partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-Emergent Adverse Event(safety and tolerability)</measure>
    <time_frame>40 months</time_frame>
    <description>Assessment of the safety and tolerability: incidence, nature and severity of treatment-related adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic complete response (pCR)</measure>
    <time_frame>40 months</time_frame>
    <description>Histological report of radical surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS).</measure>
    <time_frame>40 months</time_frame>
    <description>Recist 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS).</measure>
    <time_frame>40 months</time_frame>
    <description>time will be calculated as the interval from treatment start date to the date of death for any cause, with censoring at the date of last contact for patients alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variations of the Quality of Life</measure>
    <time_frame>40 months</time_frame>
    <description>Variations of the Quality of Life score as assessed with the Edmonton Symptom Assessment Scale (ESAS), validated in Italian language. In this quality of life there are specify 9 main symptons: the score range is from 0 to 10 for each one.
For each symptom the &quot;0 score&quot; corrisponds to &quot;no symptom present&quot; (better outcome) and the &quot;10 score&quot; corrisponds to &quot;maximum symptom assessable&quot; (worse outcome). The listed symptoms are: 1) Pain 2) Fatigue 3) Nausea 4) Depression 5) Anxiety 6) Somnolence 7) Loss of appetite 8) General Malaise 9) Dispnea. The total score is ranging from 0 to 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG-PET/CT response rate according to EORTC criteria</measure>
    <time_frame>40 months</time_frame>
    <description>to determine the rate of concordance with CT scan RECIST 1.1 response criteria and PET/CT EORTC Criteria
Complete response: complete disappearance of all target lesions with the exception of nodal disease (RECIST 1.1) and Complete resolution of FDG uptake in all lesions (EORTC)
Partial response (PR): greater than or equal to 30% decrease under baseline of the sum of target lesions (RECIST 1.1) and ≥ 25% reduction in the sum of SUVmax
Stable disease (SD): Not qualify for CR, PR or PD
Objective Progression (PD): 20% increase in the sum of diameters of target lesions or appearance of new unequivocal malignant lesions (RECIST 1.1) and ≥ 25% Increase in the sum of SUVmax or appearance of new lesions.
To evaluate the relationship existing between tumor response measured by FDG-PET/CT EORTC Criteria (mainly early PET response as evaluated at first restaging) and pCR-rate (pT0 after surgery) and progression-free survival (months).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Penile Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cabozantinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabozantinib will be administered orally at a dose of 60 mg/day continuously until 28 days prior to planned surgery or at time of the evidence of disease progression or onset of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib 60 mg/day orally</description>
    <arm_group_label>Cabozantinib</arm_group_label>
    <other_name>CABOMETYX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-75

          2. Written informed consent

          3. ECOG (Eastern Cooperative Oncology Group) performance status 0-1

          4. Cytologically or histologically proven diagnosis of PSCC.

          5. Histologically (Tru-cut biopsy) proven diagnosis of loco-regional nodal disease will
             be required in all cases except for those with clinical contraindications.

          6. Uni- or bidimensionally measurable disease as defined by RECIST v1.1 criteria.

          7. Clinical stage N2-3 and/or M1 (TNM 2002).

          8. Locoregional relapse after prior major surgery/ies (either single or multiple).

          9. No prior systemic therapy except for the administration of VBM (Vinblastine,
             Bleomycin, Methotrexate) chemotherapy for superficial disease if administered at least
             6 months prior to study enrolment.

         10. Adequate organ and marrow function .

         11. Patients must be accessible for treatment and follow up as well as they must be
             willing and capable to comply with the requirements of the study. Patients registered
             on this trial must be treated and followed at the study sponsor site.

        Exclusion Criteria:

          1. History of any one or more of the following cardiovascular conditions within the past
             6 months:

               -  Cardiac angioplasty or stenting.

               -  Myocardial infarction.

               -  Unstable angina.

               -  Coronary artery by-pass graft surgery.

               -  Symptomatic peripheral vascular disease.

               -  Class III or IV congestive heart failure, as defined by the New York Heart
                  Association (NYHA).

               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin
                  are permitted during the study but should be used with caution - please refer to
                  the study drug IB).

               -  Screening ECG with a QTc&gt;450 msec, congenital long QT syndrome, history of
                  sustained ventricular tachycardia, history of ventricular fibrillation or torsade
                  de pointes, bradycardia defined as heart rate &lt; 50 bpm (patients with a pacemaker
                  and heart rate &gt; 50 bpm are eligible).

               -  Uncontrolled hypertension.

          2. History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure
             medication for 6 months ior to first dose of study drug.

          3. History of HIV infection or active chronic hepatitis B or C.

          4. Active clinically serious infections (&gt; grade 2 NCI-CTC version 5.0).

          5. Patients with seizure disorder requiring medication (such as steroids or
             anti-epileptics).

          6. Patients undergoing renal dialysis

          7. Previous or concurrent cancer that is distinct in primary site or histology from the
             cancer being evaluated in this study EXCEPT treated basal cell carcinoma or any cancer
             curatively treated &gt; 5 years prior to study entry.

          8. History of clinically-significant gastrointestinal bleeding, inflammatory bowel
             disease, and other GI disorders associated with high risk of perforation or fistula
             formation or any other condition.

          9. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
             glucose-galactose malabsorption.

         10. Major surgery within 12 weeks before the first dose of study treatment. Complete wound
             healing from major surgery must have occurred 1 month before the first dose of study
             treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days
             before the first dose of study treatment with complete wound healing at least 10 days
             before the first dose of study treatment. Subjects with clinically relevant ongoing
             complications from prior surgery are not eligible.

         11. History of allogenic organ solid transplantation.

         12. Fertile males not willing to use a highly effective method of contraception or whose
             female partner is not using a highly effective contraception protection.

         13. Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results.

         14. Any condition that is unstable or could jeopardize the safety of the patient and their
             compliance in the study.

         15. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to study drug.

         16. Hemoptysis &gt;=2.5 ml red blood within 3 months before treatment, signs indicative of
             pulmonary hemorrhage, cavitating pulmonary lesion, tumor invading major blood vessels
             and/or GI tract, endotracheal or endobronchial tumors History of
             clinically-significant gastrointestinal bleeding, inflammatory bowel disease, or any
             other condition among those listed in the full protocol.

         17. Patients unable to swallow oral medications.

         18. Concomitant anticoagulation with oral anticoagulants or platelet inhibitors.

         19. History of cerebrovascular accident, pulmonary embolism or untreated deep venous
             thrombosis (DVT) within the past 6 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Necchi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Necchi, MD</last_name>
    <phone>+390223902402</phone>
    <email>andrea.necchi@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michela Rizzuti, Dr.ssa</last_name>
    <phone>+390223903067</phone>
    <email>michela.rizzuti@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Necchi, MD</last_name>
      <phone>+390223902402</phone>
      <email>andrea.necchi@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.</citation>
    <PMID>22237781</PMID>
  </reference>
  <reference>
    <citation>Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007 Sep-Oct;25(5):361-7. Erratum in: Urol Oncol. 2008 Jan-Feb;26(1):112. Guiliano, Anna R [corrected to Giuliano, Anna R].</citation>
    <PMID>17826651</PMID>
  </reference>
  <reference>
    <citation>Ornellas AA. Management of penile cancer. J Surg Oncol. 2008 Mar 1;97(3):199-200.</citation>
    <PMID>17918225</PMID>
  </reference>
  <reference>
    <citation>Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol. 2004 Apr;5(4):240-7. Review.</citation>
    <PMID>15050955</PMID>
  </reference>
  <reference>
    <citation>Heideman DA, Waterboer T, Pawlita M, Delis-van Diemen P, Nindl I, Leijte JA, Bonfrer JM, Horenblas S, Meijer CJ, Snijders PJ. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol. 2007 Oct 10;25(29):4550-6.</citation>
    <PMID>17925550</PMID>
  </reference>
  <reference>
    <citation>Li D, Han Z, Liu J, Zhang X, Ren J, Yan L, Liu H, Xu Z. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67. Med Oncol. 2013 Dec;30(4):702. doi: 10.1007/s12032-013-0702-9. Epub 2013 Sep 3.</citation>
    <PMID>23999841</PMID>
  </reference>
  <reference>
    <citation>Zhu Y, Li H, Yao XD, Zhang SL, Zhang HL, Shi GH, Yang LF, Yang ZY, Wang CF, Ye DW. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int. 2010;85(3):334-40. doi: 10.1159/000315432. Epub 2010 Oct 27.</citation>
    <PMID>20980789</PMID>
  </reference>
  <reference>
    <citation>Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009 Apr;27(2):141-50. doi: 10.1007/s00345-008-0302-z. Epub 2008 Jul 8. Review.</citation>
    <PMID>18607597</PMID>
  </reference>
  <reference>
    <citation>Bezerra AL, Lopes A, Santiago GH, Ribeiro KC, Latorre MR, Villa LL. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer. 2001 Jun 15;91(12):2315-21.</citation>
    <PMID>11413520</PMID>
  </reference>
  <reference>
    <citation>Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009 May;20(4):449-57. doi: 10.1007/s10552-008-9276-9. Epub 2008 Dec 11. Review.</citation>
    <PMID>19082746</PMID>
  </reference>
  <reference>
    <citation>Gregoire L, Cubilla AL, Reuter VE, Haas GP, Lancaster WD. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J Natl Cancer Inst. 1995 Nov 15;87(22):1705-9.</citation>
    <PMID>7473819</PMID>
  </reference>
  <reference>
    <citation>Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009 Oct;62(10):870-8. doi: 10.1136/jcp.2008.063149. Epub 2009 Aug 25. Review.</citation>
    <PMID>19706632</PMID>
  </reference>
  <reference>
    <citation>Rubin MA, Kleter B, Zhou M, Ayala G, Cubilla AL, Quint WG, Pirog EC. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol. 2001 Oct;159(4):1211-8.</citation>
    <PMID>11583947</PMID>
  </reference>
  <reference>
    <citation>Mannweiler S, Sygulla S, Beham-Schmid C, Razmara Y, Pummer K, Regauer S. Penile carcinogenesis in a low-incidence area: a clinicopathologic and molecular analysis of 115 invasive carcinomas with special emphasis on chronic inflammatory skin diseases. Am J Surg Pathol. 2011 Jul;35(7):998-1006. doi: 10.1097/PAS.0b013e3182147e59.</citation>
    <PMID>21681144</PMID>
  </reference>
  <reference>
    <citation>Castellsagué X, Bosch FX, Muñoz N, Meijer CJ, Shah KV, de Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, Franceschi S; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002 Apr 11;346(15):1105-12.</citation>
    <PMID>11948269</PMID>
  </reference>
  <reference>
    <citation>Backes DM, Bleeker MC, Meijer CJ, Hudgens MG, Agot K, Bailey RC, Ndinya-Achola JO, Hayombe J, Hogewoning CJ, Moses S, Snijders PJ, Smith JS. Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. Int J Cancer. 2012 Apr 15;130(8):1888-97. doi: 10.1002/ijc.26196. Epub 2011 Aug 2.</citation>
    <PMID>21618520</PMID>
  </reference>
  <reference>
    <citation>Barroso LF 2nd, Wilkin T. Human papillomavirus vaccination in males: the state of the science. Curr Infect Dis Rep. 2011 Apr;13(2):175-81. doi: 10.1007/s11908-010-0163-7.</citation>
    <PMID>21365381</PMID>
  </reference>
  <reference>
    <citation>Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ; HIV/AIDS Cancer Match Study. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006 Aug 1;20(12):1645-54.</citation>
    <PMID>16868446</PMID>
  </reference>
  <reference>
    <citation>Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer. 2005 Sep 10;116(4):606-16.</citation>
    <PMID>15825185</PMID>
  </reference>
  <reference>
    <citation>Hellberg D, Valentin J, Eklund T, Nilsson S. Penile cancer: is there an epidemiological role for smoking and sexual behaviour? Br Med J (Clin Res Ed). 1987 Nov 21;295(6609):1306-8.</citation>
    <PMID>3120988</PMID>
  </reference>
  <reference>
    <citation>Marconnet L, Rigaud J, Bouchot O. Long-term followup of penile carcinoma with high risk for lymph node invasion treated with inguinal lymphadenectomy. J Urol. 2010 Jun;183(6):2227-32. doi: 10.1016/j.juro.2010.02.025.</citation>
    <PMID>20399455</PMID>
  </reference>
  <reference>
    <citation>Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol. 2009 May;55(5):1075-88. doi: 10.1016/j.eururo.2009.02.021. Epub 2009 Feb 23. Review.</citation>
    <PMID>19264390</PMID>
  </reference>
  <reference>
    <citation>Heyns CF, Fleshner N, Sangar V, Schlenker B, Yuvaraja TB, van Poppel H. Management of the lymph nodes in penile cancer. Urology. 2010 Aug;76(2 Suppl 1):S43-57. doi: 10.1016/j.urology.2010.03.001. Review.</citation>
    <PMID>20691885</PMID>
  </reference>
  <reference>
    <citation>Pompeo AC. Extended lymphadenectomy in penile cancer. Can J Urol. 2005 Feb;12 Suppl 1:30-6; discussion 97-8.</citation>
    <PMID>15780162</PMID>
  </reference>
  <reference>
    <citation>Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol. 2005 Mar;173(3):816-9.</citation>
    <PMID>15711276</PMID>
  </reference>
  <reference>
    <citation>Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol. 2007 Mar;177(3):947-52; discussion 952.</citation>
    <PMID>17296384</PMID>
  </reference>
  <reference>
    <citation>Ornellas AA, Kinchin EW, Nóbrega BL, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol. 2008 May 1;97(6):487-95. doi: 10.1002/jso.20980.</citation>
    <PMID>18425779</PMID>
  </reference>
  <reference>
    <citation>Spiess PE, Izawa JI, Bassett R, Kedar D, Busby JE, Wong F, Eddings T, Tamboli P, Pettaway CA. Preoperative lymphoscintigraphy and dynamic sentinel node biopsy for staging penile cancer: results with pathological correlation. J Urol. 2007 Jun;177(6):2157-61.</citation>
    <PMID>17509308</PMID>
  </reference>
  <reference>
    <citation>Izawa J, Kedar D, Wong F, Pettaway CA. Sentinel lymph node biopsy in penile cancer: evolution and insights. Can J Urol. 2005 Feb;12 Suppl 1:24-9. Review.</citation>
    <PMID>15780161</PMID>
  </reference>
  <reference>
    <citation>Hungerhuber E, Schlenker B, Frimberger D, Linke R, Karl A, Stief CG, Schneede P. Lymphoscintigraphy in penile cancer: limited value of sentinel node biopsy in patients with clinically suspicious lymph nodes. World J Urol. 2006 Aug;24(3):319-24. Epub 2006 Apr 11.</citation>
    <PMID>16688459</PMID>
  </reference>
  <reference>
    <citation>Neto AS, Tobias-Machado M, Ficarra V, Wroclawski ML, Amarante RD, Pompeo AC, Del Giglio A. Dynamic sentinel node biopsy for inguinal lymph node staging in patients with penile cancer: a systematic review and cumulative analysis of the literature. Ann Surg Oncol. 2011 Jul;18(7):2026-34. doi: 10.1245/s10434-010-1546-6. Epub 2011 Feb 10. Review.</citation>
    <PMID>21308487</PMID>
  </reference>
  <reference>
    <citation>Graafland NM, Valdés Olmos RA, Meinhardt W, Bex A, van der Poel HG, van Boven HH, Nieweg OE, Horenblas S. Nodal staging in penile carcinoma by dynamic sentinel node biopsy after previous therapeutic primary tumour resection. Eur Urol. 2010 Nov;58(5):748-51. doi: 10.1016/j.eururo.2010.06.036. Epub 2010 Jul 12.</citation>
    <PMID>20633981</PMID>
  </reference>
  <reference>
    <citation>Pettaway CA, Pisters LL, Dinney CP, Jularbal F, Swanson DA, von Eschenbach AC, Ayala A. Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 1995 Dec;154(6):1999-2003.</citation>
    <PMID>7500444</PMID>
  </reference>
  <reference>
    <citation>Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA; European Association of Urology (EAU) Guidelines Group on Penile Cancer. EAU penile cancer guidelines 2009. Eur Urol. 2010 Jun;57(6):1002-12. doi: 10.1016/j.eururo.2010.01.039. Epub 2010 Feb 4.</citation>
    <PMID>20163910</PMID>
  </reference>
  <reference>
    <citation>Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA Jr, Costanzi JJ. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol. 1989 Jan;141(1):66-7.</citation>
    <PMID>2642312</PMID>
  </reference>
  <reference>
    <citation>Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol. 2008 Jul;54(1):161-8. doi: 10.1016/j.eururo.2008.04.016. Epub 2008 Apr 15.</citation>
    <PMID>18440124</PMID>
  </reference>
  <reference>
    <citation>Culkin DJ, Beer TM. Advanced penile carcinoma. J Urol. 2003 Aug;170(2 Pt 1):359-65. Review.</citation>
    <PMID>12853775</PMID>
  </reference>
  <reference>
    <citation>Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4.</citation>
    <PMID>2466471</PMID>
  </reference>
  <reference>
    <citation>Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol. 2007 Aug;52(2):488-94. Epub 2007 Feb 14.</citation>
    <PMID>17316964</PMID>
  </reference>
  <reference>
    <citation>Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int. 2006 Dec;98(6):1225-7.</citation>
    <PMID>17125480</PMID>
  </reference>
  <reference>
    <citation>Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007 Apr;177(4):1335-8.</citation>
    <PMID>17382727</PMID>
  </reference>
  <reference>
    <citation>Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 Aug 20;28(24):3851-7. doi: 10.1200/JCO.2010.29.5477. Epub 2010 Jul 12.</citation>
    <PMID>20625118</PMID>
  </reference>
  <reference>
    <citation>Graafland NM, Valdés Olmos RA, Teertstra HJ, Kerst JM, Bergman AM, Horenblas S. 18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results. Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1474-80. doi: 10.1007/s00259-010-1434-0. Epub 2010 Mar 27.</citation>
    <PMID>20349185</PMID>
  </reference>
  <reference>
    <citation>Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.</citation>
    <PMID>17960012</PMID>
  </reference>
  <reference>
    <citation>Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15.</citation>
    <PMID>17960013</PMID>
  </reference>
  <reference>
    <citation>Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.</citation>
    <PMID>16275937</PMID>
  </reference>
  <reference>
    <citation>Maiche AG. Adjuvant treatment using bleomycin in squamous cell carcinoma of penis: study of 19 cases. Br J Urol. 1983 Oct;55(5):542-4.</citation>
    <PMID>6194844</PMID>
  </reference>
  <reference>
    <citation>Protzel C, Ruppin S, Milerski S, Klebingat KJ, Hakenberg OW. [The current state of the art of chemotherapy of penile cancer: results of a nationwide survey of German clinics]. Urologe A. 2009 Dec;48(12):1495-8. doi: 10.1007/s00120-009-2108-z. German.</citation>
    <PMID>19774356</PMID>
  </reference>
  <reference>
    <citation>Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol. 1998 Nov;160(5):1770-4.</citation>
    <PMID>9783949</PMID>
  </reference>
  <reference>
    <citation>Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Fitz K, Striegel A. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol. 1991 Nov;146(5):1284-7.</citation>
    <PMID>1719241</PMID>
  </reference>
  <reference>
    <citation>Haas GP, Blumenstein BA, Gagliano RG, Russell CA, Rivkin SE, Culkin DJ, Wolf M, Crawford ED. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol. 1999 Jun;161(6):1823-5.</citation>
    <PMID>10332445</PMID>
  </reference>
  <reference>
    <citation>Pettaway CA, Pagliaro L, Theodore C, Haas G. Treatment of visceral, unresectable, or bulky/unresectable regional metastases of penile cancer. Urology. 2010 Aug;76(2 Suppl 1):S58-65. doi: 10.1016/j.urology.2010.03.082. Review.</citation>
    <PMID>20691886</PMID>
  </reference>
  <reference>
    <citation>Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009 Mar;55(3):546-51. doi: 10.1016/j.eururo.2008.07.014. Epub 2008 Jul 14.</citation>
    <PMID>18649992</PMID>
  </reference>
  <reference>
    <citation>Trabulsi EJ, Hoffman-Censits J. Chemotherapy for penile and urethral carcinoma. Urol Clin North Am. 2010 Aug;37(3):467-74. doi: 10.1016/j.ucl.2010.04.010. Review.</citation>
    <PMID>20674701</PMID>
  </reference>
  <reference>
    <citation>Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer. 1990 Feb 1;65(3):433-8.</citation>
    <PMID>2297633</PMID>
  </reference>
  <reference>
    <citation>Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2.</citation>
    <PMID>1538445</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo G, Buonerba C, Federico P, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S. Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. BJU Int. 2012 Dec;110(11 Pt B):E661-6. doi: 10.1111/j.1464-410X.2012.11453.x. Epub 2012 Sep 10.</citation>
    <PMID>22958571</PMID>
  </reference>
  <reference>
    <citation>Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RDT; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-1307. doi: 10.1093/annonc/mdn149. Epub 2008 Apr 15.</citation>
    <PMID>18417462</PMID>
  </reference>
  <reference>
    <citation>Power DG, Galvin DJ, Cuffe S, McVey GP, Mulholland PJ, Farrelly C, Delaney DW, O'Byrne KJ. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol. 2009 Mar-Apr;27(2):187-90. doi: 10.1016/j.urolonc.2007.10.015. Epub 2008 Feb 4.</citation>
    <PMID>18367122</PMID>
  </reference>
  <reference>
    <citation>Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol. 2011 Dec;60(6):1280-4. doi: 10.1016/j.eururo.2011.08.028. Epub 2011 Aug 22.</citation>
    <PMID>21871710</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Moro C, Brunelli C, Miccinesi G, Fallai M, Morino P, Piazza M, Labianca R, Ripamonti C. Edmonton symptom assessment scale: Italian validation in two palliative care settings. Support Care Cancer. 2006 Jan;14(1):30-7. Epub 2005 Jun 4.</citation>
    <PMID>15937688</PMID>
  </reference>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999 Dec;35(13):1773-82.</citation>
    <PMID>10673991</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>October 17, 2019</last_update_submitted>
  <last_update_submitted_qc>October 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

